Health Technology · Pharmaceuticals: Other · NSE: AUROPHARMA · data 2026-10-09
Aurobindo Pharma Ltd
Health check: Strong (8.2/10 on quality, valuation vs sector, growth and momentum).
Open full analysis — chart, results, balance sheet, red flags →Key figures
Price
₹1,693
Market cap
₹94,477 cr
P/E
26.5
P/B
—
ROE
9.9%
ROCE
15.1%
Debt / equity
0.21
Dividend yield
0.24%
1-year return
54.3%
52-week high
₹1,740
52-week low
₹1,080.1
Operating margin
15.1%
Growth
| Revenue (last 12 months) | ₹34,935 cr |
| Net profit (last 12 months) | ₹3,713 cr |
| Sales growth, 3 years (yearly) | 10.7% |
| Profit growth, 3 years (yearly) | 22.1% |
Similar companies
Cipla Ltd (CIPLA) · Lupin Limited (LUPIN) · Granules India Limited (GRANULES) · Sudeep Pharma Limited (SUDEEPPHRM) · Amrutanjan Health Care Limited (AMRUTANJAN)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open AUROPHARMA in NSE Scanner →